0001104659-20-002875.txt : 20200110 0001104659-20-002875.hdr.sgml : 20200110 20200110101154 ACCESSION NUMBER: 0001104659-20-002875 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20200109 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200110 DATE AS OF CHANGE: 20200110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jerash Holdings (US), Inc. CENTRAL INDEX KEY: 0001696558 STANDARD INDUSTRIAL CLASSIFICATION: APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300] IRS NUMBER: 814701719 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38474 FILM NUMBER: 20519747 BUSINESS ADDRESS: STREET 1: 260 EAST MAIN STREET STREET 2: SUITE 2706 CITY: ROCHESTER STATE: NY ZIP: 14604 BUSINESS PHONE: 2125759085 MAIL ADDRESS: STREET 1: 260 EAST MAIN STREET STREET 2: SUITE 2706 CITY: ROCHESTER STATE: NY ZIP: 14604 8-K 1 tm201714d1_8k.htm FORM 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 9, 2020

 

Jerash Holdings (US), Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38474   81-4701719
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

260 East Main Street, Suite 2706, Rochester, NY   14604
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (212) 575-9085

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   JRSH   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 9, 2020, the Board of Directors (the “Board”) of Jerash Holdings (US), Inc. (the “Company”) appointed Dr. Ibrahim H. Saif, age 54, to serve as an independent director of the Company, as the Chairman of the Compensation Committee of the Board, and as a member of the Nominating and Corporate Governance Committee and of the Audit Committee of the Board.

 

Dr. Saif is currently the CEO of Jordan Strategy Forum, an economic development think tank enabling the Jordanian private sector to engage in constructive dialogue on local economic issues and achieve comprehensive economic development. Previously, he served in the Jordanian government as the Minister of Energy and Mineral Resources from March 2015 to June 2017, and the Minister of Planning and International Cooperation from March 2013 to March 2015. Prior to his appointment as a Jordanian Minister, Dr. Saif was a Senior Scholar at the Carnegie Middle East Center, and served as a consultant to the World Bank, the International Monetary Fund, and other international organizations. Dr. Saif was also a former Director of the Center for Strategic Studies at the University of Jordan, and served as the Secretary General of the Economic and Social Counsel in Jordan. He has taught at both the University of London and Yale University, where he led courses on the economies of the Middle East. Dr. Saif holds a Doctorate in Economics, specializing in Trade, Investment, and Industrialization, and a Master’s Degree in Economics with emphasis on Development Issues, both from the University of London, as well as a Bachelor’s Degree in Economics from Yarmouk University in Jordan.

 

On January 9, 2020, the Company and Dr. Saif entered into a Director Offer Letter (the “Offer Letter”), pursuant to which Dr. Saif will be compensated at a rate of $75,000 per year, payable in cash quarterly at the end of each quarter. The Offer Letter contains customary confidentiality, non-solicitation, and indemnification provisions. The foregoing summary of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the Offer Letter, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

 

There is no family relationships between Dr. Saif and any director or executive officer of the Company. To the best knowledge of the Company, there is no understanding or arrangement between Dr. Saif and any other person pursuant to which he was appointed as a director. To the best knowledge of the Company, neither Dr. Saif nor any of his immediate family members is a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 8.01 Other Events.

 

On January 10, 2020, the Company issued a press release announcing the appointment of Dr. Saif as an independent director of the Company, which is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit Number   Exhibit
10.1   Director Offer Letter dated January 9, 2020 by and between Jerash Holdings (US), Inc. and Ibrahim H. Saif
99.1   Press Release dated January 10, 2020

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JERASH HOLDINGS (US), INC.  
       
January 10, 2020 By: /s/ Choi Lin Hung  
    Choi Lin Hung  
    Chairman of the Board of Directors, Chief Executive Officer, President, and Treasurer  

 

 

 

 

EX-10.1 2 tm201714d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

Jerash Holdings (US), Inc.

260 East Main Street, Suite 2706, Rochester, NY 14604

(212) 575-9085

 

 

January 9, 2020

 

Dr. Ibrahim H. Saif

1 Zohd Street, Rwabi Province

Swefieh

Amman

Jordan

 

Re: Director Offer Letter for An Independent Director

 

Dear Dr. Saif,

 

Jerash Holdings (US), Inc., a Delaware corporation (the “Company”), is pleased to offer you a position as of member of its board of directors (the “Board”). We believe your background and experience will be a significant asset to the Company and we look forward to your participation on the Board. Should you choose to accept this position as a member of the Board, this letter agreement (the “Agreement”) shall constitute an agreement between you and the Company and contains all the terms and conditions relating to the services you agree to provide to the Company.

 

1. Term. This Agreement is effective upon your acceptance and signature below. Subject to the provisions in Section 8 below, your term shall continue until your successor is duly elected and qualified. The position shall be up for re-election each year at the annual shareholder’s meeting, and upon re-election, the terms and provisions of this Agreement shall remain in full force and effect.

 

2. Services. You shall render services as a member of the Board and the Board committees set forth on Schedule A attached hereto (hereinafter your “Duties”). During the term of this Agreement, you shall attend and participate in such number of meetings of the Board and of the Board committee(s) of which you are a member as regularly or specially called. You may attend and participate at each such meeting via teleconference, video conference, or in person. You shall consult with the other members of the Board and Board committee(s) as necessary via telephone, electronic mail, or other forms of correspondence.

 

3. Compensation. As compensation for your services to the Company, you will receive compensation as set forth on Schedule B attached hereto (hereinafter, the “Compensation”) for serving on the Board during your term as a director. You shall be reimbursed for reasonable and approved expenses incurred by you in connection with the performance of your Duties.

 

4. No Assignment. Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by you without the prior written consent of the Company.

 

5. Confidential Information; Non-Disclosure. In consideration of your access to certain Confidential Information (as defined below) of the Company, in connection with your business relationship with the Company, you hereby represent and agree as follows:

 

a. Definition. For purposes of this Agreement the term “Confidential Information” means:

 

i. Any information which the Company possesses that has been created, discovered, or developed by or for the Company, and which has or could have commercial value or utility in the business in which the Company is engaged; or

 

ii. Any information which is related to the business of the Company and is generally not known by non-Company personnel. 

 

iii. Confidential Information includes, without limitation, trade secrets and any information concerning services provided by the Company, concepts, ideas, improvements, techniques, methods, research, data, know-how, software, formats, marketing plans, and analyses, business plans and analyses, strategies, forecasts, customer and supplier identities, characteristics and agreements.

 

1 

 

 

b. Exclusions. Notwithstanding the foregoing, the term “Confidential Information” shall not include:

 

i. Any information which becomes generally available to the public other than as a result of a breach of the confidentiality portions of this Agreement, or any other agreement requiring confidentiality between the Company and you;

 

ii. Information received from a third party in rightful possession of such information who is not restricted from disclosing such information; and

 

iii. Information known by you prior to receipt of such information from the Company, which prior knowledge can be documented.

 

c. Documents. You agree that, without the express written consent of the Company, you will not remove from the Company's premises, any notes, formulas, programs, data, records, machines, or any other documents or items which in any manner contain or constitute Confidential Information, nor will you make reproductions or copies of same. You shall promptly return any such documents or items, along with any reproductions or copies, to the Company upon the earliest of Company's demand, termination of this Agreement, or your termination or Resignation, as defined in Section 8 herein.

 

d. Confidentiality. You agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or indirectly, any Confidential Information or anything relating to such information without the prior written consent of the Company, except as maybe necessary in the course of your business relationship with the Company. You further agree that you will not use any Confidential Information without the prior written consent of the Company, except as may be necessary in the course of your business relationship with the Company, and that the provisions of this paragraph (d) shall survive termination of this Agreement.

 

e. Ownership. You agree that Company shall own all right, title, and interest (including patent rights, copyrights, trade secret rights, mask work rights, trademark rights, and all other intellectual and industrial property rights of any sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas, and information made or conceived or reduced to practice, in whole or in part, by you during the term of this Agreement and that arise out of your Duties (collectively, “Inventions”) and you will promptly disclose and provide all Inventions to the Company. You agree to assist the Company, at its expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights assigned.

 

6. Non-Competition. You agree and undertake that you will not, so long as you are a member of the Board and for a period of 24 months following termination of this Agreement for whatever reason, directly or indirectly as owner, partner, joint venture, shareholder, employee, broker, agent principal, corporate officer, director, licensor, or in any other capacity whatsoever, engage in, become financially interested in, be employed by, or have any connection with any business or venture that is engaged in any activities involving services or products which compete, directly or indirectly, with the services or products provided or proposed to be provided by the Company or its subsidiaries or affiliates; provided, however, that you may own securities of any public corporation which is engaged in such business but in an amount not to exceed at any one time, one percent of any class of stock or securities of such company, so long as you has no active role in the publicly owned company as director, employee, consultant, or otherwise. 

 

7. Non-Solicitation. So long as you are a member of the Board and for a period of 24 months thereafter, you shall not directly or indirectly solicit for employment any individual who was an employee of the Company during your tenure.

 

8. Termination and Resignation. Your membership on the Board may be terminated for any or no reason by a vote of the shareholders holding at least a majority of the shares of the Company’s issued and outstanding shares entitled to vote or, alternatively, by a written resolution adopted by the shareholders holding at least a majority of the shares of the Company’s issued and outstanding shares entitled to vote. Your membership on the Board or on any Board committee shall be terminated if you become of unsound mind or are prohibited by law from being so. Your membership on any Board committee will be terminated on the same effective date when your membership on the Board is terminated. You may also terminate your membership on the Board or on any Board committee for any or no reason by delivering your written notice of resignation to the Company (“Resignation”), and such Resignation shall be effective upon the time specified therein or, if no time is specified, upon receipt of the notice of Resignation by the Company. Upon the effective date of the termination or Resignation, your right to compensation hereunder will be subject to the Company’s obligations to pay you any compensation (including the vested portion of the Shares) that you have already earned and to reimburse you for approved expenses already incurred in connection with your performance of your Duties as of the effective date of such termination or Resignation. Any Shares that have not vested as of the effective date of such termination or Resignation shall be forfeited and cancelled.

 

2 

 

 

9. Governing Law. All questions with respect to the construction and/or enforcement of this Agreement, and the rights and obligations of the parties hereunder, shall be determined in accordance with the law of the State of New York applicable to agreements made and to be performed entirely in the State of New York.

 

10. Entire Agreement; Amendment; Waiver; Counterparts. This Agreement expresses the entire understanding with respect to the subject matter hereof and supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof. Any term of this Agreement may be amended and observance of any term of this Agreement may be waived only with the written consent of the parties hereto. Waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of any subsequent breach or failure of the same term or condition or waiver of any other term or condition of this Agreement. The failure of any party at any time to require performance by any other party of any provision of this Agreement shall not affect the right of any such party to require future performance of such provision or any other provision of this Agreement. This Agreement may be executed in separate counterparts each of which will be an original and all of which taken together will constitute one and the same agreement, and may be executed using facsimiles of signatures, and a facsimile of a signature shall be deemed to be the same, and equally enforceable, as an original of such signature.

 

11. Indemnification. The Company shall, to the maximum extent provided under applicable law, indemnify and hold you harmless from and against any expenses, including reasonable attorney’s fees, judgments, fines, settlements, and other legally permissible amounts (“Losses”), incurred in connection with any proceeding arising out of, or related to, your performance of your Duties, other than any such Losses incurred as a result of your negligence or willful misconduct. The Company shall advance to you any expenses, including reasonable attorneys’ fees and costs of settlement, incurred in defending any such proceeding to the maximum extent permitted by applicable law. Such costs and expenses incurred by you in defense of any such proceeding shall be paid by the Company in advance of the final disposition of such proceeding promptly upon receipt by the Company of (a) written request for payment; (b) appropriate documentation evidencing the incurrence, amount, and nature of the costs and expenses for which payment is being sought; and (c) an undertaking adequate under applicable law made by or on your behalf to repay the amounts so advanced if it shall ultimately be determined pursuant to any non-appealable judgment or settlement that you are not entitled to be indemnified by the Company.

 

12. Not an Employment Agreement. This Agreement is not an employment agreement, and shall not be construed or interpreted to create any right for you to continue employment with the Company.

 

13. Acknowledgement. You accept this Agreement subject to all the terms and provisions of this Agreement. You agree to accept as binding, conclusive, and final all decisions or interpretations of the Board of the Company of any questions arising under this Agreement.

 

[Signature page follows]

 

 

3 

 

 

The Agreement has been executed and delivered by the undersigned and is made effective as of the date set first set forth above.

 

  Sincerely,
   
 

Jerash Holdings (US), Inc.

   
   
   /s/ Choi Lin Hung  
  By: Choi Lin Hung  
  Title: Chairman of the Board, Chief Executive Officer, President, and Treasurer  

  

 

 

AGREED AND ACCEPTED:
   
/s/ Ibrahim H. Saif  
By: Ibrahim H. Saif  

 

4 

 

 

Schedule A

 

The Director is offered to serve on the following Board committee(s):

 

Committee Title
Audit Committee Member
Nominating and Corporate Governance Committee Member
Compensation Committee Member and Chairman

 

 

5 

 

 

Schedule B

Compensation

 

During your term as a member of the Board, you will receive cash compensation in the amount of US$75,000 per year, which shall be paid to you quarterly at the end of each quarter.

 

 

6 

 

 

EX-99.1 3 tm201714d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Jerash Appoints Dr. Ibrahim Saif to Board of Directors

 

Rochester, New York – January 10, 2020 – Jerash Holdings (US), Inc. (Nasdaq: JRSH) (the “Company” or “Jerash”), a producer of high-quality textile goods for leading global brands, is pleased to announce that Dr. Ibrahim Saif has been appointed to the Company's Board of Directors, effective January 9, 2020, as an independent director. Dr. Saif has been actively involved in senior government economic and international ministry roles for the country of Jordan, as well as academic roles focused on economics and the Middle East.

 

Sam Choi, Chairman and CEO of Jerash, said, “We welcome Dr. Saif to the Board at Jerash and look forward to leveraging his expertise as we continue to expand our manufacturing and employment base in Jordan. Dr. Saif’s ongoing work as CEO of the Jordan Strategy Forum has centered on strengthening the role of the private sector in the sustainable development of Jordan and creating prosperity for Jordanians. These goals align perfectly to Jerash’s efforts as a socially responsible employer seeking to expand our business interests in the country and drive profitability for our shareholders. Dr. Saif also brings extensive insights into global economics and business in the Middle East through his experience as a consultant to global thought leaders such as the International Monetary Fund and the World Bank.”

 

Dr. Saif is currently the CEO of Jordan Strategy Forum, an economic development think tank enabling the Jordanian private sector to engage in constructive dialogue on local economic issues and achieve comprehensive economic development. Previously, he served the country of Jordan as the Minister of Energy and Mineral Resources from March 2015 to June 2017, and the Minister of Planning and International Cooperation from March 2013 until March 2015. Prior to his appointment as a Jordanian Minister, Dr. Saif was a Senior Scholar at the Carnegie Middle East Center, a former Director of the Center for Strategic Studies at the University of Jordan, and served as the Secretary General of the Economic and Social Council in Jordan. He has taught at both the University of London and Yale University, where he led courses on the economies of the Middle East. Dr. Saif holds a Doctorate in Economics, specializing in Trade, Investment and Industrialization, and a Master’s Degree in Economics with emphasis on Development Issues, both from the University of London, as well as a Bachelor’s Degree in Economics from Yarmouk University in Jordan.

 

About Jerash Holdings (US), Inc.

Jerash Holdings (US), Inc. (Nasdaq: JRSH) is a manufacturer utilized by many well-known brands and retailers, such as Walmart, Costco, Hanes, Columbia, VF Corporation (which owns brands such as The North Face, Timberland, Jansport, etc.), and PVH Corp. (which owns brands such as Calvin Klein, Tommy Hilfiger, IZOD, Speedo, etc.). Its production facilities are currently made up of four factory units and three warehouses and it currently employs approximately 3,900 people. The total annual capacity at its facilities was approximately 8.0 million pieces as of the end of calendar year 2019. Additional information is available at http://www.jerashholdings.com.

 

 

  

 

Forward Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect Jerash’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including those risks described from time to time in filings made by Jerash with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Statements contained in this news release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Jerash does not intend and does not assume any obligation to update these forward-looking statements, other than as required by law.

 

Contact:

Matt Kreps, Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

 

 

GRAPHIC 4 image_001.jpg GRAPHIC begin 644 image_001.jpg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